BD announced plans to invest more than $35 million and add approximately 50 new jobs to expand prefilled flush syringe manufacturing at its Columbus, Neb. facility to increase the resiliency of the U.S. health care system.
The investments will support new BD PosiFlush Prefilled Flush Syringe production lines, product innovation and operational efficiencies, enabling BD to produce hundreds of millions of additional units annually to meet growing demand from U.S. hospitals and health systems.
"BD PosiFlush Syringes are essential to everyday patient care for keeping catheters clear and safely delivering medications," said Eric Borin, worldwide president of BD Medication Delivery Solutions. "Our latest investments boost U.S. production capacity and reinforce our commitment to a reliable supply for health care providers and the patients they serve."
This announcement builds on the company's broader commitment to strengthening U.S. health care infrastructure and ensuring long-term supply resilience. Earlier this year, BD announced its intention to invest $2.5 billion in U.S. manufacturing capacity over the next five years, further strengthening its position as one of the largest U.S. manufacturers of medical devices. This includes more than $40 million in investments across its U.S. manufacturing network to expand capacity for syringes, needles and IV catheters – products essential to everyday clinical care.
Comments powered by CComment